OWCP (OWC Pharmaceutical Research) YoY EBITDA Growth: 25.00% (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research YoY EBITDA Growth?

OWC Pharmaceutical Research OWCP -90.00% YoY EBITDA Growth is 25.00% as of Sep. 2019.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. OWC Pharmaceutical Research's YoY EBITDA Growth for the quarter that ended in Sep. 2019 was 25.00%.

OWC Pharmaceutical Research's EBITDA per Share for the three months ended in Sep. 2019 was $-0.00.

OWC Pharmaceutical Research YoY EBITDA Growth Related Terms

OWC Pharmaceutical Research YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research YoY EBITDA Growth Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only -506.25 79.38 -10.00 -40.91 -122.58

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 -410.00 28.57 33.33 25.00

OWC Pharmaceutical Research YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

OWC Pharmaceutical Research's YoY EBITDA Growth for the fiscal year that ended in Dec. 2018 is calculated as:

YoY EBITDA Growth (A: Dec. 2018 )
=(EBITDA per Share (A: Dec. 2018 )-EBITDA per Share (A: Dec. 2017 ))/ | EBITDA per Share (A: Dec. 2017 ) |
=(-0.069--0.031)/ | -0.031 |
=-122.58 %

OWC Pharmaceutical Research's YoY EBITDA Growth for the quarter that ended in Sep. 2019 is calculated as:

YoY EBITDA Growth (Q: Sep. 2019 )
=(EBITDA per Share (Q: Sep. 2019 )-EBITDA per Share (Q: Sep. 2018 )) / | EBITDA per Share (Q: Sep. 2018 )) |
=(-0.003--0.004)/ | -0.004 |
=25.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 25.00% mean?
OWC Pharmaceutical Research (OWCP) has a YoY EBITDA Growth of 25.00% as of Sep. 2019. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's YoY EBITDA Growth too high?
OWC Pharmaceutical Research's current YoY EBITDA Growth is 25.00%.
How does OWC Pharmaceutical Research's YoY EBITDA Growth compare to PARNF and CANB?
OWC Pharmaceutical Research's YoY EBITDA Growth of 25.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for OWC Pharmaceutical Research and its competitors. OWC Pharmaceutical Research's current YoY EBITDA Growth is 25.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current YoY EBITDA Growth of 25.00%. The current YoY EBITDA Growth is 25.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current YoY EBITDA Growth is 25.00% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.